Is Genmab A/S (GMAB) Stock Undervalued After Positive Epkinly DLBCL Trial Results?
TheFly reported on July 2 that H.C. Wainwright analyst Raghuram Selvaraju increased the price target on GMAB to $40 from $38 while reaffirming a Buy rating on the shares.







